$AMAT, $BMY, $CTLT, $CELG, $DCP, $FDX
Below is a list of Wall Street’s Top analysts outlook for Key issues for Thursday, as follows:
Applied Materials Inc. (NASDAQ:AMAT) was reinstated as Buy with an 80 price objective at Merrill Lynch. The firm sees 35% upside now, with its secular chip demand growth migrating into a less cyclical industry.
Bristol-Myers Squibb Co. (NYSE:BMY) was reiterated as Buy with a 75 price target at Argus. The independent research firm noted that its immuno-oncology drug Opdivo has moved closer to approval as a first-line combination treatment for non-small-cell lung cancer.
Catelent Inc. (NYSE:CTLT) was raised to Outperform from Market Perform at Raymond James. The stock closed at 40.52 and has a 52-wk trading range of 27.48 – 47.87.
Celgene Corp. (NASDAQ:CELG) was started with an Overweight rating and assigned a 110 price target at JPMorgan. Celgene has a 52-wk trading range of 86.55 – 147.17, and it has a consensus analyst target price of 118.72.
DCP Midstream L.P. (NYSE:DCP) was raised to Buy from Neutral with a 42 price objective at Merrill Lynch.
FedEx Corp. (NYSE:FDX) was raised to Buy from Hold with a 295 price target at Stifel. Credit Suisse maintained its Outperform rating but lowered its price target to 306 from 314 around a messy Quarter despite positive developments.
Latest posts by Paul Ebeling (see all)
- The Street’s Key Stock Analysts Research Reports - June 18, 2019
- Asia: Gold, USD, Crude Oil, Stocks & Commodities - June 18, 2019
- President Trump’s $16-B Farm Bailout Criticized at the WTO - June 18, 2019